OVID Ovid Therapeutics Inc.

-0.01  -1%
Previous Close 1.73
Open 1.72
Price To Book 1.16
Market Cap 66551991
Shares 38,693,018
Volume 144,562
Short Ratio
Av. Daily Volume 687,899

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data due 2H 2019.
OV101 (gaboxadol)
Fragile X syndrome
Phase 1/2 data released December 17, 2018 met primary endpoint of safety and tolerability.
Developmental and Epileptic Encephalopathies (dEE)
Phase 3 trial planned for 2H 2019.
Adolescents with Angelman syndrome
Phase 2 trial initiation announced September 24, 2018.
Developmental and Epileptic Encephalopathies (dEE) - younger patient population
Phase 1b/2a enrolment to be completed 2H 2019.
TAK-935/OV935 - ARCADE
CDKL5 Deficiency

Latest News

  1. Ovid Therapeutics Reports First Quarter 2019 Financial Results
  2. Ovid Therapeutics Rallies On Rare Genetic Disorder Drug Data
  3. Have Insiders Been Buying Ovid Therapeutics Inc. (NASDAQ:OVID) Shares This Year?
  4. Ovid Therapeutics to Present at the American Academy of Neurology 71st Annual Meeting
  5. Ovid Therapeutics Announces Senior Management Changes to Align Expertise with Advancing Clinical Stage Pipeline
  6. Ovid Therapeutics Announces Appointment of Pharmaceutical Veteran, Thomas Perone, as Senior Vice President, General Counsel and Corporate Secretary
  7. Ovid Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
  8. Ovid Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference on Monday, March 11
  9. Why A Secondary Offering Is Often Negative For Stocks
  10. Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock
  11. The Daily Biotech Pulse: Teva Settles With FTC, Setback For Merck In Liver Cancer Trial, Sienna Biopharma Offering
  12. Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
  13. Zynerba Stock Is Marijuana-Adjacent Play Worth a Look
  14. How Much Of Ovid Therapeutics Inc. (NASDAQ:OVID) Do Insiders Own?
  15. Ovid Therapeutics Announces Phase 1b/2a Results of OV935/TAK-935 in Adults with Rare Epilepsies
  16. Ovid Therapeutics Announces Plans to Move into a Phase 3 Trial in Pediatric Patients Based on End-of-Phase 2 Meeting for OV101 in Angelman Syndrome
  17. Ovid Therapeutics Announces OV935/TAK-935 Presentations at the American Epilepsy Society 72nd Annual Meeting
  18. Granite Point Capital’s Returns, AUM, and Holdings
  19. Ovid Therapeutics to Present at 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27
  20. Ovid Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Recent Clinical Progress